Abstract
CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) plus rituximab is a standard chemotherapy used to treat patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). However, among elderly patients, this regimen has not been completely satisfactory in its efficacy and safety. We report our clinical experience in 8 collaborative institutions to determine if the VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone, and bleomycin) combination therapy plus rituximab was effective and safe to treat elderly patients with aggressive B-NHL. Between September 2004 and December 2007, 23 previously untreated patients, median age 73 years, 50.0% classified as high-intermediate/high-risk on the standard International Prognostic Index (IPI) entered this trial. Complete remission rate was 90.5%, with a 100% overall response rate (RR) at the end of induction therapy; overall survival (OS) rate at 3 years was 76.4% (median follow-up 744 days), with an 82.6% 3-year progression-free survival (PFS) rate (median follow-up 744 days). The most common grade 3/4 toxicities were hematologic, including neutropenia in 75.0% of the patients despite prophylactic administration of granulocyte colony-stimulating fac...Continue Reading
References
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jan 18, 2003·Blood·Eva OsbyUNKNOWN Nordic Lymphoma Group
Jul 3, 2003·Clinical Lymphoma·John D HainsworthF Anthony Greco
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J K DoorduijnP Sonneveld
Sep 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard I Fisher
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Apr 25, 2006·Cancer Science·Michinori OguraKensei Tobinai
May 2, 2006·The Lancet Oncology·Michael PfreundschuhUNKNOWN MabThera International Trial Group
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Jul 29, 2006·Blood·Marinus H J van OersAnton Hagenbeek
Sep 2, 2006·Blood·Roswitha ForstpointnerUNKNOWN German Low Grade Lymphoma Study Group (GLSG)
Nov 3, 2006·Archives of Gerontology and Geriatrics·László VáróczyArpád Illés
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Nov 9, 2007·Leukemia & Lymphoma·Mariapaola FinaPier Luigi Zinzani
Dec 13, 2007·International Journal of Health Services : Planning, Administration, Evaluation·Ryuichi Komatsu, Takashi Sawada
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel O PerskyUNKNOWN Southwest Oncology Group
Jun 25, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake
Citations
Jan 5, 2012·Cancer Chemotherapy and Pharmacology·Ho-Jin ShinGoon-Jae Cho
Oct 21, 2010·Cancer·Antonino MusolinoAndrea Ardizzoni
Apr 5, 2018·Leukemia & Lymphoma·Sara BeygiJohn Lister
Dec 8, 2017·Acta Clinica Belgica·Emanuele CenciniMonica Bocchia